◆ TICKERBASEインタラクティブ表示 →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
ホーム › 全銘柄 › AUROPHARMA · English version

Aurobindo Pharma Limited (AUROPHARMA)

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

Healthcare · ウォール街（米国） · 最終更新: 2026-09-20

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas.

主要指標

インタラクティブチャートと全財務諸表を見る →

年次損益計算書

損益計算書2026-03-312025-03-312024-03-312023-03-31
売上高合計₹333.8B₹313.8B₹287.0B₹246.2B
売上総利益₹190.6B₹176.4B₹154.7B₹127.2B
営業利益（EBIT）₹51.9B₹50.5B₹44.4B₹25.4B
当期純利益₹35.0B₹34.9B₹31.7B₹19.3B

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は AUROPHARMA のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/AUROPHARMA

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.